Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Clinical trial NCT04685070 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04685070
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-14
- Primary completion
- 2022-12-31
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.